Sanjay Goel, MD
Medical Oncology · New Brunswick, NJNPI 1104906692
Payments from drug & device makers
Across 1,202 payments — averaging $4259.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$893K
- Genentech, Inc.$747K
- Takeda Pharmaceuticals U.S.A., Inc.$738K
- Deciphera Pharmaceuticals Inc.$568K
- Pfizer$472K
- Amgen$364K
- plus $1.3M from 28 others
Across 20 payments — averaging $252.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
- Regeneron$1K
- GSK$1K
What the payments were for
- Consulting fees$8,95769%
- Speaking & faculty fees$2,05016%
- Travel & lodging$1,49811%
- Food & beverage$4163%
- Education$1111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 320 | $893,129 |
| Genentech, Inc. | 40 | $747,172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 98 | $737,566 |
| Deciphera Pharmaceuticals Inc. | 245 | $568,090 |
| Pfizer | 39 | $471,898 |
| Amgen | 14 | $364,031 |
| AstraZeneca | 15 | $324,066 |
| Tesaro, Inc. | 28 | $142,963 |
| EMD Serono, Inc. | 97 | $125,714 |
| Beigene, Ltd. | 99 | $113,943 |
| Epizyme, Inc. | 8 | $108,469 |
| Eisai Inc. | 26 | $91,096 |
| Regeneron | 6 | $84,266 |
| Incyte Corporation | 96 | $70,426 |
| Beigene AUS Pty Ltd | 3 | $64,102 |
| Roche Products Limited | 8 | $48,117 |
| Jazz Pharmaceuticals Inc. | 3 | $46,096 |
| GSK | 19 | $37,389 |
| Seagen Inc. | 13 | $37,077 |
| E.r. Squibb & Sons, L.L.C. | 6 | $19,708 |
| Astrazeneca UK Limited | 3 | $13,066 |
| Eli Lilly | 1 | $6,747 |
| Merck | 4 | $1,783 |
| Array Biopharma Inc | 1 | $1,700 |
| Daiichi Sankyo Inc. | 1 | $795 |
| Novartis | 1 | $350 |
| Sanofi | 1 | $350 |
| Regeneron Healthcare Solutions, Inc. | 1 | $101 |
| Astellas Pharma US Inc | 1 | $78 |
| Bayer | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Bausch & Lomb Americas Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,120,365 in reported general payments places this provider in the 90th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 11 | $6 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New Brunswick
- Kristen SpencerNew Brunswick$7.2M
- Biren SaraiyaNew Brunswick$6.2M
- Mridula GeorgeNew Brunswick$4.5M
- Missak HaigentzNew Brunswick$3.9M
- Dale SchaarNew Brunswick$1.5M
- Sarah WeissNew Brunswick$1.5M
- Patrick BolandNew Brunswick$1.3M
- Roman GroisbergNew Brunswick$965K
- Tina MayerNew Brunswick$560K
- Kevin DavidNew Brunswick$430K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.